Results 211 to 220 of about 26,068 (276)

Beyond “One‐Size‐Fits‐All”: Deconstructing the Hormonal Determinants of Sodium Sensitivity in Treated Hypertension

The Journal of Clinical Hypertension, Volume 28, Issue 5, May 2026.
Dae‐Hee Kim
wiley   +1 more source

Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Zaheen M, Ferdous F, Amarasekera AT, Petutschnigg J, Edelmann F, Tan TC.   +5 more
europepmc   +1 more source

Monitoring renal safety in mineralocorticoid receptor antagonist trials [PDF]

European Journal of Heart Failure, 2017
openaire   +2 more sources

Cardiovascular Outcomes and Hyperkalemia Risk in Patients With Diabetes, Chronic Kidney Disease and Heart Failure: A Real-World Comparison of Non-steroidal versus Steroidal Mineralocorticoid Receptor Antagonists. [PDF]

Cureus
Okunlola AO, Kolawole O, Otabor E, Hassan A, Hamilton M, Alomari L, Lam J, Idowu AB.   +7 more
europepmc   +1 more source

Mineralocorticoid Receptor Antagonists and Cognitive Outcomes in Cardiovascular Disease and Beyond: A Systematic Review. [PDF]

J Pers Med
Pastena P, Campagnoli G, Rahmani AR, Kalogeropoulos AP.   +3 more
europepmc   +1 more source

Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. [PDF]

Front Pharmacol
Wang TY, Zhang L, Wang HY, Jiang FF.
europepmc   +1 more source

Erratum: Author Corrections to "The Effect of Mineralocorticoid Receptor Antagonists on Heart Failure with Nonreduced Ejection Fraction: A Systematic Review and Meta-Analysis [CJC Open. Volume 7, Issue 10, Pages 1332-1344. doi:10.1016/j.cjco.2025.05.021]". [PDF]

CJC Open
De Luca C, Bhatt H, Gupta A, Yahyavi A, Banivaheb B, Rayner D, Anderson K, Zieroth S, Virani SA, Foroutan F, Aleksova N.   +10 more
europepmc   +1 more source

Discontinuation and reinitiation of mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction. [PDF]

Eur J Heart Fail
Landucci L, Faxén UL, Benson L, Dahlström U, Carrero JJ, Savarese G, Lund LH.   +6 more
europepmc   +1 more source

Aldosterone's impact on kidney health: exploring the benefits of mineralocorticoid receptor antagonists for renal protection. [PDF]

Am J Transl Res
Liu Z, Xie B, Pang S, Xie Y, Jili M, Mo Z, Li W, Yang R.   +7 more
europepmc   +1 more source

Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death across cardio-kidney-metabolic diseases: A meta-analysis of randomized clinical trials. [PDF]

Eur J Heart Fail
Marques P, Zannad F, Ferreira JP.
europepmc   +1 more source